CSPC Pharmaceutical Group Limited — Cyborg Score 7/10
Strong
Pharmaceuticals & Biotechnology
Strategic Profile
CSPC operates with innovative drugs as its core strategy, focusing on therapeutic areas including nervous system diseases, oncology, anti-infectives, and cardiovascular disease. The company maintains strong competitive positioning through vertical integration—manufacturing both active pharmaceutical ingredients (APIs) and formulations—and has established strategic collaborations including one with AstraZeneca for obesity and type 2 diabetes treatments.
Cyborg Score Rationale
CSPC demonstrates solid fundamentals with increasing profitability (92.93% net income growth in latest half-year), attractive dividend yield (5.44%), and broad portfolio diversification across 1,000+ products in seven therapeutic areas. Market leadership position and strategic partnerships with global pharma leaders support strength, though exposure to Chinese regulatory environment presents moderate headwind.
Top Insights
Finished drugs segment dominates revenue at approximately 80%, providing stable earnings base while oncology and nervous system therapeutics drive growth
Strategic AstraZeneca collaboration on obesity/diabetes treatments positions company in high-growth therapeutic categories
Strong dividend profile (5.44% yield) appeals to income investors with payout ratio of 65.03%
Vertical integration across APIs and formulations provides cost advantage and supply chain control in competitive Chinese market
Named Competitors
China Pharmaceutical Group — State-owned Chinese pharma conglomerate
Sino Biopharma — Chinese pharmaceutical manufacturer and innovator
China Biologic Products — Chinese specialty pharmaceutical company
Recent Developments
Latest half-year net income reached HKD 2.74B (Feb 2026), representing 92.93% growth
Market capitalization at HKD 105.09B as of February 2026
Q4 2025 earnings release projected for March 24, 2026
Open the full interactive CSPC Pharmaceutical Group Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.